Frontlight ResearchEarly access
Taking peoplePhase 2
Levosimendan in Cardiac Arrest: A Randomized Double-blinded Clinical Phase II Trial (LeICA)
Key facts
- Who runs it
- Karolinska University Hospital
- Where
- Sweden1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 14 Apr 2026
- Expected to end
- 30 Jun 2027
- Type of study
- Interventional
- Record updated
- 11 June 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Witnessed OHCA
- Prompt start of CPR (within 2 minutes)
- First recorded rhythm VF or pVT, or PEA in case of suspected pulmonary embolism (as determined by the attending physician)
- Refractory cardiac arrest, i.e. sustained beyond third rhythm check
- Intravenous access
- Age 18-75 years
Who cannot take part
- Traumatic cause of cardiac arrest
- Time to administration of study drug >30 min after onset of cardiac arrest
- Known pre-existing severe neurological or systemic disease (e.g. severe dementia, current advanced malignancy, advanced cardiac or pulmonary disease, terminal chronic kidney disease on dialysis)
- First recorded rhythm asystole
- Known or apparent pregnancy
- Known pre-existing (i.e. current) DNACPR decision
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Cardiac arrest
This trial is currently available in Sweden.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate if a single dose of levosimendan given during cardiopulmonary resuscitation (CPR) for out-of-hospital cardiac arrest (OHCA) increases 30-day survival compared to placebo.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
Download the PDF
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Criteria questions
- Built from 2024-517279-20-02, who can take part
- Record updated
- 11 June 2025